Management and 3-month outcomes of isolated superficial vein thrombosis of the lower limb: A real-world cohort study

•Fondaparinux was granted a European market authorization for SVT treatment.•In France, fondaparinux is currently the first drug prescribed in SVT by vascular physicians.•SVT drug prescriptions, dosage and duration continue to vary widely.•The study supports the extrapolability of CALISTO results in...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Thrombosis research 2017-09, Vol.157, p.117-119
Hauptverfasser: Blin, P., Sevestre, M.A., Pouchain, D., Gillet, J.L.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•Fondaparinux was granted a European market authorization for SVT treatment.•In France, fondaparinux is currently the first drug prescribed in SVT by vascular physicians.•SVT drug prescriptions, dosage and duration continue to vary widely.•The study supports the extrapolability of CALISTO results in every-day practice.
ISSN:0049-3848
1879-2472
DOI:10.1016/j.thromres.2017.07.009